OneSource Specialty Pharma Ltd Q2 FY26 – From Biosimilars to Billion Dreams: ₹3,758 mn Revenue, 37% EBITDA Growth, and a USD 136 mn Twist of Drama
1. At a Glance
OneSource Specialty Pharma Ltd (OSSPL) is India’s biotech Cinderella story — except the fairy godmother is Strides Pharma, and the pumpkin is a ₹20,408 crore market cap CDMO beast riding the biosimilar wave. The company’s September 2025 quarter results read like a Bollywood biopic of redemption: consolidated revenue of ₹3,758 million (₹376 crore), up 12% YoY, and a 37% jump in EBITDA to ₹1,065 million (₹106.5 crore). PAT clocked ₹104.85 million (₹10.5 crore), a heroic 128% leap from the same quarter last year.
At ₹1,782 per share, the stock trades at a “what-the-heck” P/E of 148, with a price-to-book ratio of 3.49 — clearly, the market has more faith in science than spreadsheets. ROE stands at 3.34% and ROCE at 5.52%, signalling that the labs are busy, but the cash registers haven’t caught up yet. Debt is ₹1,295 crore — not catastrophic, but definitely the kind that keeps the CFO awake at night.
Exports form 31% of revenues, domestic 69%, and 98% of revenue comes from contract development and manufacturing — or in plain English, OneSource does all the hard work while global pharma giants take the glory.
Still, with USFDA approvals, ANVISA certification, and a USD 136 million claim under review, OSSPL is living the ultimate biotech soap opera.
2. Introduction
Imagine a pharma company that began life as a corporate offspring, went through a demerger, changed names twice, and is now in a multi-billion-dollar identity crisis — that’s OneSource Specialty Pharma. Born in 2007, OSSPL started as part of Strides Pharma’s intricate CDMO web, eventually merging the scattered pieces of Strides, Steriscience, and Biopharma units into one singular, sterile super-entity.
The transformation was completed in early 2024 when Stelis Biopharma morphed into OneSource Specialty Pharma Ltd — possibly after HR realised the old name sounded too much like a biology lecture.
Today, the company operates as a Contract Development and Manufacturing Organisation (CDMO) — the unsung hero behind many biotech breakthroughs. It doesn’t own blockbuster drugs; it builds them for others. Think of OSSPL as the biotech version of Foxconn: your phone might say Apple, but someone else’s factory made it.
While investors salivate at its “bio” tag, OSSPL’s path hasn’t been all smooth pipettes. From 2021 to 2024, it was deep in the red, losing ₹800 crore in FY23. Then came a turnaround story in FY25 — ₹1,445 crore in sales and a PAT of ₹40 crore. The miracle? A 32% operating margin. The reality check? A 148x P/E.
Still, markets love a good narrative. And OSSPL’s narrative — of sterile injectables, biologics, and global regulatory approvals — fits perfectly into India’s new biotech dream.
3. Business Model – WTF Do They Even Do?
OneSource is the science nerd of India’s pharma class. It doesn’t sell your regular paracetamol — it deals in complex biologics, biosimilars, and injectables that require more lab coats than marketing budgets.
Its three main business verticals: a) Biologics – The holy grail of modern pharma. OSSPL develops biologics and biosimilars for global partners, including antibody-based drugs. b) Soft Gelatin Capsules – Legacy from Strides’ oral business; think nutraceuticals and prescription gels. c) Complex Drug-Device Combinations – Think inhalers, auto-injectors, and other James Bond gadgets for medicine.
The business runs on an integrated CDMO model, offering end-to-end services — from clinical trials to commercial production. It handles pre-clinical research, tech transfer, regulatory documentation, and commercial supply. Essentially, if big pharma wants a vaccine or biologic without building its own plant, it knocks on OSSPL’s door.
With two EU-GMP and USFDA-approved facilities in Karnataka covering 85,000+ sq. meters and 400 million annual drug units, OSSPL’s infrastructure screams “ready for scale.” Yet, the financials whisper “still warming up.”
4. Financials Overview
Metric
Latest Qtr (Sep 2025)
YoY Qtr (Sep 2024)
Prev Qtr (Jun 2025)
YoY %
QoQ %
Revenue (₹ mn)
3,758
3,341
3,270
12.5%
14.9%
EBITDA (₹ mn)
1,065
776
880
37.2%
21.0%
PAT (₹ mn)
105
46
-0
128%
N.A.
EPS (₹)
0.92
0.42
–
119%
—
Annualised EPS = ₹0.92 × 4 = ₹3.68. At ₹1,782/share, P/E = 484x (based on annualised EPS — yes, the math hurts).
Commentary: OneSource’s margins are juiced up like a biotech stock
